NASDAQ$AMED

Amedisys Inc · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Briefing

Amedisys reported a decrease in net service revenue but an increase in net income for Q2 2020, and reissued its full year 2020 guidance.

Amedisys reported a decrease in net service revenue to $485.0 million compared to $493.0 million in 2019. Net income attributable to Amedisys, Inc. increased to $34.7 million compared to $33.7 million in 2019. The company reissued its full year 2020 guidance, anticipating net service revenue in the range of $2.040 billion to $2.070 billion and adjusted diluted earnings per share in the range of $4.84 to $5.06.

  • Net service revenue decreased to $485.0 million compared to $493.0 million in 2019.
  • Net income attributable to Amedisys, Inc. increased to $34.7 million compared to $33.7 million in 2019.
  • Adjusted net income attributable to Amedisys, Inc. per diluted share was $1.34 compared to $1.21 in 2019.
  • The company reissued its full year 2020 guidance.

Headline financials

Total Revenue

$485M

Previous: $493M-1.6%
EPS (adj)

$1.34

Previous: $1.21+10.7%
Capital Expenditures

$267K

Previous: $1.5M-82.1%
Free Cash Flow

$134M

Previous: $57.8M+131.4%
Net Income

$34.7M

Previous: $33.7M+2.8%
Operating Income

$49.9M

Previous: $44.8M+11.6%
Gross Profit

$190M

Previous: $202M-6.1%
Cash & Equivalents

$177M

Previous: $13.9M+1175.2%
Total Assets

$1.65B

Previous: $1.21B+36.5%
Stock-Based Comp

$6.73M

Previous: $5.54M+21.4%

Revenue & EPS history

Amedisys · Revenue · Quarterly

$485M

Q2 2020-1.6%vs Q2 2019
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Forward guidance

Amedisys anticipates net service revenue to be in the range of $2.040 billion to $2.070 billion. Adjusted EBITDA is anticipated to be in the range of $245 million to $255 million. Adjusted diluted earnings per share is anticipated to be in the range of $4.84 to $5.06 based on an estimated 33.4 million shares outstanding. This guidance excludes the effects of any future acquisitions, if any are made.

Tailwinds

  • Net service revenue is anticipated to be in the range of $2.040 billion to $2.070 billion.
  • Adjusted EBITDA is anticipated to be in the range of $245 million to $255 million.
  • Adjusted diluted earnings per share is anticipated to be in the range of $4.84 to $5.06.
  • Guidance is based on an estimated 33.4 million shares outstanding.
  • The guidance excludes the effects of any future acquisitions.

Headwinds

  • The home health, hospice and personal care industries are highly competitive.
  • The industries are subject to intensive regulations.
  • Trends are subject to numerous factors, risks, and uncertainties.
  • The guidance excludes the effects of any future acquisitions, if any are made.
  • Forward-looking statements are inherently subject to risks and uncertainties.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 15 quarterly earnings reports

Historical avg

-0.6%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-5.0%

Avg return

30 days after

46%

32 / 70 earnings

Positive

+25.6%

Q2 2014

Best reaction

-25.3%

Q3 2013

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025
Q2 2025+1.2%+1.0%
Q1 2025+0.2%-0.8%-1.6%
Q4 2024+0.1%+0.6%+1.5%
Q3 2024+0.9%-3.4%-10.4%
Q2 2024+0.0%+0.5%-0.2%
Q1 2024+0.0%+0.8%+5.5%
Q4 2023+0.9%+0.6%-1.6%
Q3 2023-0.8%-1.1%+1.8%
Q2 2023-0.6%-0.2%+2.5%
Q1 2023+4.2%+3.9%+2.8%
Q4 2022+5.4%+2.2%-23.6%
Q3 2022-9.0%-4.2%-10.7%
Q2 2022-3.8%+0.9%-4.5%
Q1 2022+0.4%-3.3%-10.5%
Q4 2021+5.8%+14.5%+18.4%
Q3 2021+0.1%+1.7%-20.2%
Q2 2021-22.8%-22.9%-29.3%
Q1 2021+0.2%
Q4 2020-6.2%
Q3 2020-1.9%
Q2 2020+3.7%
Q1 2020-3.3%
Q4 2019-2.1%
Q3 2019-1.5%
Q2 2019-1.9%
Q1 2019-6.3%
Q4 2018+0.0%
Q3 2018+17.3%
Q2 2018+11.1%
Q1 2018+7.2%
Q4 2017+2.3%
Q3 2017+4.8%
Q2 2017-20.9%
Q1 2017+4.4%
Q4 2016+4.7%
Q3 2016-10.1%
Q2 2016-7.1%
Q1 2016-7.0%
Q4 2015+12.3%
Q3 2015+10.8%
Q2 2015-3.2%
Q1 2015+6.0%
Q4 2014-5.4%
Q3 2014+16.2%
Q2 2014+25.6%
Q1 2014-1.0%
Q4 2013-10.0%
Q3 2013-25.3%
Q2 2013+17.8%
Q1 2013-2.8%
Q4 2012-8.7%
Q3 2012-5.0%
Q2 2012+12.5%
Q1 2012-1.2%
Q4 2011-0.6%
Q3 2011-23.8%
Q2 2011-10.7%
Q1 2011-6.4%
Q4 2010-8.0%
Q3 2010+1.3%
Q2 2010-7.9%
Q1 2009-4.3%
Q1 2010+2.6%
Q4 2007-1.3%
Q4 2009-1.3%
Q3 2008-5.7%
Q3 2009-5.7%
Q4 2008+7.6%
Q2 2008+7.6%
Q2 2009+7.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro